Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748572 | 0.88 | PAX8 (0.32) | PAX8PGD | |
| SCHEMBL9807659 | 0.82 | PAX8 (0.36) | PAX8 | |
| SCHEMBL20889 | 0.82 | PAX8 (0.36) | PAX8 | |
| SCHEMBL1774725 | 0.80 | SMN1; SMN2 (0.33) | SMN1; SMN2PAX8 | |
| SCHEMBL17748583 | 0.79 | PAX8 (0.36) | PAX8 | |
| SCHEMBL17748597 | 0.79 | GRM8 (0.41) | PAX8 | |
| SCHEMBL1788967 | 0.79 | PAX8 (0.41) | PAX8 | |
| SCHEMBL17767378 | 0.79 | PAX8 (0.41) | PAX8 | |
| SCHEMBL18585443 | 0.78 | PDE4A (0.44) | SMN1; SMN2PGD | |
| SCHEMBL7217308 | 0.78 | PDE4A (0.44) | SMN1; SMN2PGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943598-B2 | Use of organic glucosamine salts | BIOIBERICA, S.A. (ES) | 2011-05-17 | — | — | US | claimed |
| EP-1781304-B1 | USE OF ORGANIC GLUCOSAMINE SALTS | BIOIBERICA (ES) | 2009-09-09 | — | — | EP | claimed |
| US-20070244070-A1 | Use of Organic Glucosamine Salts | BIOIBERICA, S.A. (ES) | 2007-10-18 | — | — | US | claimed |
| EP-1781304-A1 | USE OF ORGANIC GLUCOSAMINE SALTS | BIOIBERICA, S.A. (ES) | 2007-05-09 | — | — | EP | claimed |
| WO-2006012951-A1 | USE OF ORGANIC GLUCOSAMINE SALTS | BIOIBERICA, S.A. (ES) | 2006-02-09 | — | — | WO | claimed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | claimed |
| EP-1238669-B1 | Neutrophil function inhibitors which contain glucosamine | DAINICHISEIKA COLOR CHEM (JP) | 2004-08-18 | — | — | EP | claimed |
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | claimed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | claimed |
| US-6627621-B2 | Neutrophil function inhibitors | DAINICHIESEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2003-09-30 | — | — | US | claimed |
| US-20020128230-A1 | Neutrophil function inhibitors | KOYO CHEMICAL CO., LTD. (JP) | 2002-09-12 | — | — | US | claimed |
| EP-1238669-A2 | Neutrophil function inhibitors which contain glucosamine | Dainichiseika Color & Chemicals Mfg. Co., Ltd. (JP) | 2002-09-11 | — | — | EP | claimed |
| US-20190246667-A1 | Calcium-Fortified Beverages and Method of Making Thereof | TROPICANA PROD INC (US) | 2019-08-15 | — | — | US | disclosed |
| EP-2222193-B1 | CALCIUM-FORTIFIED BEVERAGES AND METHOD OF MAKING THEREOF | TROPICANA PROD INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20150037465-A1 | Calcium-Fortified Beverages and Method of Making Thereof | TROPICANA PRODUCTS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-7943598-B2 | Use of organic glucosamine salts | BIOIBERICA, S.A. (ES) | 2011-05-17 | — | — | US | disclosed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | disclosed |
| US-6627621-B2 | Neutrophil function inhibitors | DAINICHIESEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20020128230-A1 | Neutrophil function inhibitors | KOYO CHEMICAL CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-1238669-A2 | Neutrophil function inhibitors which contain glucosamine | Dainichiseika Color & Chemicals Mfg. Co., Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | CUTA, HIRA, HARS1 | SMN1; SMN2 4162/4885PAX8 3014/4885PGD 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.